Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 280-287

  Zollner, Sabine B ^a   Raquet, Elmar ^a   Müller Cohrs, Jochen ^a   Metzner, Hubert J ^a   Weimer, Thomas ^a   Pragst, Ingo ^a   Dickneite, Gerhard ^a   Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

hemostasis factor VIII; preclinical recombinant; rVIII SingleChain

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8 SINGLE CHAIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAPLORHINI; HEMOPHILIA A; HEMOSTASIS; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; RAT; THROMBUS;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE; ACTIVATED RECOMBINANT FACTOR VIII; ADA; ANTI-DRUG ANTIBODY; APCC; APTT; AREA UNDER THE CURVE; AUC; AUC FROM 0 TO 24HOURS; AUC FROM 0 TO LAST TIMEPOINT; AUC(0-24H); AUC(0-LAST); B-DOMAIN DELETED; BDD; C(MAX); CFT; CHINESE HAMSTER OVARY; CHO; CI; CLOT FORMATION TIME; CLOTTING TIME; CONFIDENCE INTERVAL; CT; ELISA; ENDOGENOUS THROMBIN POTENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETP; FACTOR VIII; FVIII; GLP; GOOD LABORATORY PRACTICE; HALF-LIFE; HEMOSTASIS; MAXIMUM CONCENTRATION; POTENTIATION OF THROMBUS FORMATION; PRECLINICAL; PTF; RECOMBINANT; RECOMBINANT FACTOR VIII; RFVIII; RFVIIIA; RVIII-SINGLECHAIN; T(1/2); T(MAX); TGA; THROMBIN GENERATION ASSAY; TIME TAKEN TO ACHIEVE C(MAX); VON WILLEBRAND FACTOR; VWF;

ANIMALS; BLOOD COAGULATION FACTORS; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMANS; MALE; MICE; MICE, KNOCKOUT; RABBITS; RANDOM ALLOCATION; RECOMBINANT PROTEINS;

EID: 84883770241     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.06.017     Document Type: Article

References (27)

1. S. Schulte Pioneering designs for recombinant coagulation factors Thromb Res 128 Suppl. 1 2011 S9 S12
2. P.H. Bolton-Maggs, and K.J. Pasi Haemophilias A and B Lancet 361 2003 1801 1809
3. D. Keeling, C. Tait, and M. Makris Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology Haemophilia 14 2008 671 684
4. A. Srivastava, A.K. Brewer, E.P. Mauser-Bunschoten, N.S. Key, S. Kitchen, and A. Llinas Guidelines for the management of hemophilia Haemophilia 19 2013 e1 e47
5. T. Wong, and M. Recht Current options and new developments in the treatment of haemophilia Drugs 71 2011 305 320
6. M. Franchini, and G. Lippi Recombinant factor VIII concentrates Semin Thromb Hemost 36 2010 493 497
7. C. Sheridan Hemophilia market awaits next-generation therapies Nat Biotechnol 29 2011 960
8. S. Ehrenforth, W. Kreuz, I. Scharrer, R. Linde, M. Funk, and T. Gungor Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs Lancet 339 1992 594 598
9. C.R. Hay, B. Palmer, E. Chalmers, R. Liesner, R. Maclean, and S. Rangarajan Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom Blood 117 2011 6367 6370
10. J. Wight, and S. Paisley The epidemiology of inhibitors in haemophilia A: a systematic review Haemophilia 9 2003 418 435
11. S. Bjorkman, and E. Berntorp Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia Clin Pharmacokinet 40 2001 815 832
12. S. Bjorkman, A. Folkesson, and S. Jonsson Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A Eur J Clin Pharmacol 65 2009 989 998
13. S. Schmidbauer, R. Witzel, J. Kreuter, S. Schwingal, L. Robbel, and P. Sebastian Characterization of recombinant single chain FVIII, rVIII-SingleChain (CSL627) Haemophilia 18 2012 37
14. P. Hossler, S.F. Khattak, and Z.J. Li Optimal and consistent protein glycosylation in mammalian cell culture Glycobiology 19 2009 936 949
15. L. Bi, A.M. Lawler, S.E. Antonarakis, K.A. High, J.D. Gearhart, and H.H. Kazazian Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat Genet 10 1995 119 121
16. A.R. Giles, M. Johnston, H. Hoogendoorn, M. Blajchman, and J. Hirsh The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits Thromb Res 17 1980 353 366
17. D.E. Sabatino, T.C. Nichols, E. Merricks, D.A. Bellinger, R.W. Herzog, and P.E. Monahan Animal models of hemophilia Prog Mol Biol Transl Sci 105 2012 151 209
18. ® Pfizer Scientific Discussion [online] http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000232/WC500049003.pdf/ 2012 [Accessed 27/03/13]
19. ® http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/ approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm056051/2012 [Accessed: 27/03/2013]
20. ® Baxter Healthcare Scientific Discussion [online] http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific- Discussion/human/000520/WC500022464.pdf/ 2012 [Accessed 27/03/2013]
21. ® Bayer Scientific Discussion [online] http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000232/WC500049003.pdf/ 2012 [Accessed 27/03/2013]
22. T. Kawasaki, T. Kaida, J. Arnout, J. Vermylen, and M.F. Hoylaerts A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic Thromb Haemost 81 1999 306 311
23. S. Wessler Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis J Clin Invest 34 1955 647 651
24. D.P. Thomas Venous thrombosis and the "Wessler test" Thromb Haemost 76 1996 1 4
25. P.W. Kamphuisen, J.C. Eikenboom, and R.M. Bertina Elevated factor VIII levels and the risk of thrombosis Arterioscler Thromb Vasc Biol 21 2001 731 738
26. G.A. Vehar, B. Keyt, D. Eaton, H. Rodriguez, D.P. O'Brien, and F. Rotblat Structure of human factor VIII Nature 312 1984 337 342
27. Y. Sawamoto, R. Prescott, D. Zhong, E.L. Saenko, E. Mauser-Bunschoten, and K. Peerlinck Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors Thromb Haemost 79 1998 62 68